Last updated on August 2019

A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Brief description of study

The main objective of this study is to evaluate the safety and efficacy of ABBV-105, upadacitinib, and ABBV-599 vs placebo for the treatment of signs and symptoms of SLE in participants with moderately to severely active SLE and to define doses for further development.

Clinical Study Identifier: NCT03978520

Find a site near you

Start Over

Instituto CAICI /ID# 211633

Rosario, Santa FE, Argentina
  Connect »